Hayashi T, Nonaka S, Bandoh N, Kobayashi Y, Imada M, Harabuchi Y
Department of Otolaryngology, Asahikawa Medical College, Asahikawa, Hokkaido, Japan.
Cancer. 2001 Sep 15;92(6):1495-503. doi: 10.1002/1097-0142(20010915)92:6<1495::aid-cncr1474>3.0.co;2-p.
Optimal treatment policies of maxillary sinus carcinoma remain to be defined.
Seventy-four patients with squamous cell carcinoma of maxillary sinus were treated at Department of Otolaryngology, Asahikawa Medical College between 1983 and 1997. The T classification according to the 1997 International Union Against Cancer was as follows: 9 with T2, 35 with T3, and 30 with T4. Eight patients had lymph node metastasis with N1 at diagnosis. Of 62 patients who started multimodality therapy that comprised preoperative radiochemotherapy including local irradiation with total dose of 50 grays along with concomitant intramaxillary arterial infusion of 5-fluorouracil with total dose of 5000 mg followed by total or partial maxillectomy, 59 received the complete therapy. Eleven patients had to be treated with radiotherapy alone, and 1 patient received postoperative radiotherapy. The median follow-up time for surviving patients was 117 months.
The 5-year overall survival, disease free survival, and local control (LC) rates for all patients were 58.5%, 63.7%, and 73.6%, respectively. The patients who underwent multimodality therapy showed significantly better 5-year overall survival, disease free survival, and LC rates as compared with those who underwent radiotherapy alone (68.5% vs. 9.1%; 73.2% vs. 18.2%; 84.0% vs. 18.2%; P < 0.0001 each). Multivariate analysis revealed that T classification and treatment modality are independent predictors for disease free survival.
The authors' treatment method, which did not include any complicated techniques, produced higher survival and LC rates because of high effectiveness of multimodality therapy. They concluded that their multimodality therapy could offer a better chance for cure from maxillary sinus carcinoma at many institutions.
上颌窦癌的最佳治疗策略仍有待确定。
1983年至1997年间,旭川医科大学耳鼻喉科对74例上颌窦鳞状细胞癌患者进行了治疗。根据1997年国际抗癌联盟的T分类如下:T2期9例,T3期35例,T4期30例。8例患者诊断时伴有N1淋巴结转移。62例患者开始接受多模式治疗,包括术前放化疗,局部照射总剂量为50格雷,同时上颌动脉内注入5-氟尿嘧啶总剂量为5000毫克,随后进行全上颌骨或部分上颌骨切除术,其中59例完成了全部治疗。11例患者仅接受放疗,1例患者接受术后放疗。存活患者的中位随访时间为117个月。
所有患者的5年总生存率、无病生存率和局部控制(LC)率分别为58.5%、63.7%和73.6%。与仅接受放疗的患者相比,接受多模式治疗的患者5年总生存率、无病生存率和LC率显著更高(分别为68.5%对9.1%;73.2%对18.2%;84.0%对18.2%;P均<0.0001)。多变量分析显示,T分类和治疗方式是无病生存的独立预测因素。
作者的治疗方法不包括任何复杂技术,由于多模式治疗的高效性,产生了更高的生存率和LC率。他们得出结论,他们的多模式治疗可以为许多机构的上颌窦癌患者提供更好的治愈机会。